CVS Health Corporation (CVS) Stock Competitors & Peer Comparison
See (CVS) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Healthcare Plans Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| CVS | $97.37 | +0.30% | 123.8B | 42.56 | $2.28 | +2.74% |
| UNH | $406.03 | -0.13% | 374.8B | 31.06 | $13.29 | +2.15% |
| ANTM | $482.58 | +2.71% | 114.6B | 18.99 | $25.41 | +1.00% |
| ELV | $407.94 | -2.44% | 92.2B | 17.99 | $23.60 | +1.61% |
| CI | $296.15 | +2.26% | 78B | 2.59 | $113.71 | +2.09% |
| HUM | $367.35 | +3.19% | 43.6B | 38.79 | $9.36 | +0.97% |
| CNC | $64.81 | -0.35% | 32.7B | -5.07 | -$13.05 | N/A |
| MOH | $197.38 | -0.52% | 10.6B | 54.58 | $3.72 | N/A |
| OSCR | $27.98 | +2.15% | 7.1B | -50.41 | -$0.54 | N/A |
| ALHC | $20.67 | +34.67% | 4B | 192.00 | $0.10 | N/A |
Stock Comparison
CVS vs UNH Comparison June 2026
CVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CVS stands at 123.8B. In comparison, UNH has a market cap of 374.8B. Regarding current trading prices, CVS is priced at $97.37, while UNH trades at $406.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CVS currently has a P/E ratio of 42.56, whereas UNH's P/E ratio is 31.06. In terms of profitability, CVS's ROE is +0.04%, compared to UNH's ROE of +0.12%. Regarding short-term risk, CVS is less volatile compared to UNH. This indicates potentially lower risk in terms of short-term price fluctuations for CVS.Check UNH's competition here
CVS vs ANTM Comparison June 2026
CVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CVS stands at 123.8B. In comparison, ANTM has a market cap of 114.6B. Regarding current trading prices, CVS is priced at $97.37, while ANTM trades at $482.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CVS currently has a P/E ratio of 42.56, whereas ANTM's P/E ratio is 18.99. In terms of profitability, CVS's ROE is +0.04%, compared to ANTM's ROE of +0.12%. Regarding short-term risk, CVS is less volatile compared to ANTM. This indicates potentially lower risk in terms of short-term price fluctuations for CVS.Check ANTM's competition here
CVS vs ELV Comparison June 2026
CVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CVS stands at 123.8B. In comparison, ELV has a market cap of 92.2B. Regarding current trading prices, CVS is priced at $97.37, while ELV trades at $407.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CVS currently has a P/E ratio of 42.56, whereas ELV's P/E ratio is 17.99. In terms of profitability, CVS's ROE is +0.04%, compared to ELV's ROE of +0.12%. Regarding short-term risk, CVS is less volatile compared to ELV. This indicates potentially lower risk in terms of short-term price fluctuations for CVS.Check ELV's competition here
CVS vs CI Comparison June 2026
CVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CVS stands at 123.8B. In comparison, CI has a market cap of 78B. Regarding current trading prices, CVS is priced at $97.37, while CI trades at $296.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CVS currently has a P/E ratio of 42.56, whereas CI's P/E ratio is 2.59. In terms of profitability, CVS's ROE is +0.04%, compared to CI's ROE of +0.15%. Regarding short-term risk, CVS is less volatile compared to CI. This indicates potentially lower risk in terms of short-term price fluctuations for CVS.Check CI's competition here
CVS vs HUM Comparison June 2026
CVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CVS stands at 123.8B. In comparison, HUM has a market cap of 43.6B. Regarding current trading prices, CVS is priced at $97.37, while HUM trades at $367.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CVS currently has a P/E ratio of 42.56, whereas HUM's P/E ratio is 38.79. In terms of profitability, CVS's ROE is +0.04%, compared to HUM's ROE of +0.06%. Regarding short-term risk, CVS is less volatile compared to HUM. This indicates potentially lower risk in terms of short-term price fluctuations for CVS.Check HUM's competition here
CVS vs CNC Comparison June 2026
CVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CVS stands at 123.8B. In comparison, CNC has a market cap of 32.7B. Regarding current trading prices, CVS is priced at $97.37, while CNC trades at $64.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CVS currently has a P/E ratio of 42.56, whereas CNC's P/E ratio is -5.07. In terms of profitability, CVS's ROE is +0.04%, compared to CNC's ROE of -0.29%. Regarding short-term risk, CVS is less volatile compared to CNC. This indicates potentially lower risk in terms of short-term price fluctuations for CVS.Check CNC's competition here
CVS vs MOH Comparison June 2026
CVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CVS stands at 123.8B. In comparison, MOH has a market cap of 10.6B. Regarding current trading prices, CVS is priced at $97.37, while MOH trades at $197.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CVS currently has a P/E ratio of 42.56, whereas MOH's P/E ratio is 54.58. In terms of profitability, CVS's ROE is +0.04%, compared to MOH's ROE of +0.04%. Regarding short-term risk, CVS is less volatile compared to MOH. This indicates potentially lower risk in terms of short-term price fluctuations for CVS.Check MOH's competition here
CVS vs OSCR Comparison June 2026
CVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CVS stands at 123.8B. In comparison, OSCR has a market cap of 7.1B. Regarding current trading prices, CVS is priced at $97.37, while OSCR trades at $27.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CVS currently has a P/E ratio of 42.56, whereas OSCR's P/E ratio is -50.41. In terms of profitability, CVS's ROE is +0.04%, compared to OSCR's ROE of -0.03%. Regarding short-term risk, CVS is less volatile compared to OSCR. This indicates potentially lower risk in terms of short-term price fluctuations for CVS.Check OSCR's competition here
CVS vs ALHC Comparison June 2026
CVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CVS stands at 123.8B. In comparison, ALHC has a market cap of 4B. Regarding current trading prices, CVS is priced at $97.37, while ALHC trades at $20.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CVS currently has a P/E ratio of 42.56, whereas ALHC's P/E ratio is 192.00. In terms of profitability, CVS's ROE is +0.04%, compared to ALHC's ROE of +0.11%. Regarding short-term risk, CVS is less volatile compared to ALHC. This indicates potentially lower risk in terms of short-term price fluctuations for CVS.Check ALHC's competition here
CVS vs CLOV Comparison June 2026
CVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CVS stands at 123.8B. In comparison, CLOV has a market cap of 2.2B. Regarding current trading prices, CVS is priced at $97.37, while CLOV trades at $4.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CVS currently has a P/E ratio of 42.56, whereas CLOV's P/E ratio is -35.75. In terms of profitability, CVS's ROE is +0.04%, compared to CLOV's ROE of -0.17%. Regarding short-term risk, CVS is less volatile compared to CLOV. This indicates potentially lower risk in terms of short-term price fluctuations for CVS.Check CLOV's competition here
CVS vs BHG Comparison June 2026
CVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CVS stands at 123.8B. In comparison, BHG has a market cap of 130.5M. Regarding current trading prices, CVS is priced at $97.37, while BHG trades at $16.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CVS currently has a P/E ratio of 42.56, whereas BHG's P/E ratio is -0.12. In terms of profitability, CVS's ROE is +0.04%, compared to BHG's ROE of -0.70%. Regarding short-term risk, CVS is less volatile compared to BHG. This indicates potentially lower risk in terms of short-term price fluctuations for CVS.Check BHG's competition here
CVS vs CABR Comparison June 2026
CVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CVS stands at 123.8B. In comparison, CABR has a market cap of 18M. Regarding current trading prices, CVS is priced at $97.37, while CABR trades at $1.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CVS currently has a P/E ratio of 42.56, whereas CABR's P/E ratio is -1.77. In terms of profitability, CVS's ROE is +0.04%, compared to CABR's ROE of -3.00%. Regarding short-term risk, CVS is less volatile compared to CABR. This indicates potentially lower risk in terms of short-term price fluctuations for CVS.Check CABR's competition here
CVS vs BMGL Comparison June 2026
CVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CVS stands at 123.8B. In comparison, BMGL has a market cap of 12M. Regarding current trading prices, CVS is priced at $97.37, while BMGL trades at $0.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CVS currently has a P/E ratio of 42.56, whereas BMGL's P/E ratio is -1.45. In terms of profitability, CVS's ROE is +0.04%, compared to BMGL's ROE of -1.95%. Regarding short-term risk, CVS is less volatile compared to BMGL. This indicates potentially lower risk in terms of short-term price fluctuations for CVS.Check BMGL's competition here
CVS vs MRAI Comparison June 2026
CVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CVS stands at 123.8B. In comparison, MRAI has a market cap of 9.2M. Regarding current trading prices, CVS is priced at $97.37, while MRAI trades at $0.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CVS currently has a P/E ratio of 42.56, whereas MRAI's P/E ratio is -0.09. In terms of profitability, CVS's ROE is +0.04%, compared to MRAI's ROE of +0.50%. Regarding short-term risk, CVS is more volatile compared to MRAI. This indicates potentially higher risk in terms of short-term price fluctuations for CVS.Check MRAI's competition here
CVS vs GTS Comparison June 2026
CVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CVS stands at 123.8B. In comparison, GTS has a market cap of 0. Regarding current trading prices, CVS is priced at $97.37, while GTS trades at $35.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CVS currently has a P/E ratio of 42.56, whereas GTS's P/E ratio is 10.41. In terms of profitability, CVS's ROE is +0.04%, compared to GTS's ROE of +0.07%. Regarding short-term risk, CVS is more volatile compared to GTS. This indicates potentially higher risk in terms of short-term price fluctuations for CVS.Check GTS's competition here
CVS vs AET Comparison June 2026
CVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CVS stands at 123.8B. In comparison, AET has a market cap of 0. Regarding current trading prices, CVS is priced at $97.37, while AET trades at $106.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CVS currently has a P/E ratio of 42.56, whereas AET's P/E ratio is N/A. In terms of profitability, CVS's ROE is +0.04%, compared to AET's ROE of +0.11%. Regarding short-term risk, CVS is more volatile compared to AET. This indicates potentially higher risk in terms of short-term price fluctuations for CVS.Check AET's competition here
CVS vs MGLN Comparison June 2026
CVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CVS stands at 123.8B. In comparison, MGLN has a market cap of 0. Regarding current trading prices, CVS is priced at $97.37, while MGLN trades at $94.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CVS currently has a P/E ratio of 42.56, whereas MGLN's P/E ratio is 8.49. In terms of profitability, CVS's ROE is +0.04%, compared to MGLN's ROE of +0.00%. Regarding short-term risk, CVS is more volatile compared to MGLN. This indicates potentially higher risk in terms of short-term price fluctuations for CVS.Check MGLN's competition here
CVS vs UAM Comparison June 2026
CVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CVS stands at 123.8B. In comparison, UAM has a market cap of 0. Regarding current trading prices, CVS is priced at $97.37, while UAM trades at $1.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CVS currently has a P/E ratio of 42.56, whereas UAM's P/E ratio is N/A. In terms of profitability, CVS's ROE is +0.04%, compared to UAM's ROE of +0.17%. Regarding short-term risk, CVS is more volatile compared to UAM. This indicates potentially higher risk in terms of short-term price fluctuations for CVS.Check UAM's competition here